421P Survival benefit of long-term (Beyond 2 years) atezolizumab in 1L ES-SCLC: Exploratory analysis of four phase III trials

comparisons between subgroups difficult.Limitations of this meta-analysis included heterogeneity of study populations and follow-up durations. Conclusions:This meta-analysis demonstrates the comparability in efficacy and safety of PD-(L)1 inhibitors for 1L ES-SCLC in both Asian and non-Asian pts.More realworld evidence at the regional level will confirm long-term clinical benefits and tolerability in specific pt populations.